A Phase 1B Study of Dulanermin in Combination With Modified FOLFOX6 Plus Bevacizumab in Patients With Metastatic Colorectal Cancer

Micro-Abstract Dulanermin, a human recombinant form of Apo2 ligand/tumor necrosis factor–related apoptosis-inducing ligand with proapoptotic activity in cancer cells, was tested in this phase 1B study in combination with FOLFOX and bevacizumab in the first-line treatment of patients with advanced co...

Full description

Saved in:
Bibliographic Details
Published in:Clinical colorectal cancer 2013-12, Vol.12 (4), p.248-254
Main Authors: Wainberg, Zev A, Messersmith, Wells A, Peddi, Parvin F, Kapp, Amy V, Ashkenazi, Avi, Royer-Joo, Stephanie, Portera, Chia C, Kozloff, Mark F
Format: Article
Language:English
Subjects:
Adult
Aged
Antibodies, Monoclonal, Humanized - administration & dosage
Antibodies, Monoclonal, Humanized - adverse effects
Antineoplastic Combined Chemotherapy Protocols - administration & dosage
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Apo2L/TRAIL
Apoptosis
Bevacizumab
Colorectal Neoplasms - drug therapy
Colorectal Neoplasms - pathology
Death receptor
Disease-Free Survival
Dulanermin
Female
Fluorouracil - administration & dosage
Fluorouracil - adverse effects
FOLFOX
Gastroenterology and Hepatology
Hematology, Oncology and Palliative Medicine
Humans
Leucovorin - administration & dosage
Leucovorin - adverse effects
Male
Maximum Tolerated Dose
Metastatic colorectal cancer
Middle Aged
Neoplasm Metastasis
Organoplatinum Compounds - administration & dosage
Organoplatinum Compounds - adverse effects
TNF-Related Apoptosis-Inducing Ligand - administration & dosage
TNF-Related Apoptosis-Inducing Ligand - adverse effects
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Micro-Abstract Dulanermin, a human recombinant form of Apo2 ligand/tumor necrosis factor–related apoptosis-inducing ligand with proapoptotic activity in cancer cells, was tested in this phase 1B study in combination with FOLFOX and bevacizumab in the first-line treatment of patients with advanced colorectal cancer. The combination was found to be well tolerated in the 23 patients treated with no dose-limiting toxicity and with evidence of efficacy.
ISSN:1533-0028
1938-0674
DOI:10.1016/j.clcc.2013.06.002